S&P 500   4,274.21 (+0.02%)
DOW   33,556.50 (-0.19%)
QQQ   353.22 (-0.28%)
AAPL   169.95 (-1.17%)
MSFT   311.11 (-0.33%)
META   292.75 (-2.08%)
GOOGL   129.47 (+0.70%)
AMZN   125.33 (-0.52%)
TSLA   238.05 (-2.49%)
NVDA   422.00 (+0.69%)
NIO   8.43 (+0.24%)
BABA   85.80 (-0.13%)
AMD   97.42 (+1.52%)
T   14.86 (-1.07%)
F   12.32 (-0.88%)
MU   67.45 (-0.72%)
CGC   0.90 (-2.07%)
GE   110.28 (+0.32%)
DIS   79.58 (-0.59%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.07 (-3.16%)
NFLX   377.94 (-0.35%)
S&P 500   4,274.21 (+0.02%)
DOW   33,556.50 (-0.19%)
QQQ   353.22 (-0.28%)
AAPL   169.95 (-1.17%)
MSFT   311.11 (-0.33%)
META   292.75 (-2.08%)
GOOGL   129.47 (+0.70%)
AMZN   125.33 (-0.52%)
TSLA   238.05 (-2.49%)
NVDA   422.00 (+0.69%)
NIO   8.43 (+0.24%)
BABA   85.80 (-0.13%)
AMD   97.42 (+1.52%)
T   14.86 (-1.07%)
F   12.32 (-0.88%)
MU   67.45 (-0.72%)
CGC   0.90 (-2.07%)
GE   110.28 (+0.32%)
DIS   79.58 (-0.59%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.07 (-3.16%)
NFLX   377.94 (-0.35%)
S&P 500   4,274.21 (+0.02%)
DOW   33,556.50 (-0.19%)
QQQ   353.22 (-0.28%)
AAPL   169.95 (-1.17%)
MSFT   311.11 (-0.33%)
META   292.75 (-2.08%)
GOOGL   129.47 (+0.70%)
AMZN   125.33 (-0.52%)
TSLA   238.05 (-2.49%)
NVDA   422.00 (+0.69%)
NIO   8.43 (+0.24%)
BABA   85.80 (-0.13%)
AMD   97.42 (+1.52%)
T   14.86 (-1.07%)
F   12.32 (-0.88%)
MU   67.45 (-0.72%)
CGC   0.90 (-2.07%)
GE   110.28 (+0.32%)
DIS   79.58 (-0.59%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.07 (-3.16%)
NFLX   377.94 (-0.35%)
S&P 500   4,274.21 (+0.02%)
DOW   33,556.50 (-0.19%)
QQQ   353.22 (-0.28%)
AAPL   169.95 (-1.17%)
MSFT   311.11 (-0.33%)
META   292.75 (-2.08%)
GOOGL   129.47 (+0.70%)
AMZN   125.33 (-0.52%)
TSLA   238.05 (-2.49%)
NVDA   422.00 (+0.69%)
NIO   8.43 (+0.24%)
BABA   85.80 (-0.13%)
AMD   97.42 (+1.52%)
T   14.86 (-1.07%)
F   12.32 (-0.88%)
MU   67.45 (-0.72%)
CGC   0.90 (-2.07%)
GE   110.28 (+0.32%)
DIS   79.58 (-0.59%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.07 (-3.16%)
NFLX   377.94 (-0.35%)
NASDAQ:TXG

10x Genomics (TXG) Stock Forecast, Price & News

$41.29
+0.43 (+1.05%)
(As of 02:22 PM ET)
Compare
Today's Range
$40.45
▼
$41.69
50-Day Range
$40.86
▼
$62.98
52-Week Range
$23.81
▼
$63.57
Volume
448,469 shs
Average Volume
962,656 shs
Market Capitalization
$4.85 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$58.73
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

10x Genomics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
43.7% Upside
$58.73 Price Target
Short Interest
Bearish
4.30% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.73
Upright™ Environmental Score
News Sentiment
0.93mentions of 10x Genomics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$4.68 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.76) to ($1.32) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.41 out of 5 stars

Medical Sector

146th out of 963 stocks

Analytical Instruments Industry

10th out of 27 stocks

See Top Rated MarketRank™ Stocks Here

TXG stock logo

About 10x Genomics (NASDAQ:TXG) Stock

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

TXG Price History

TXG Stock News Headlines

September 20, 2023 | americanbankingnews.com
10x Genomics (NASDAQ:TXG) Receives "Buy" Rating from Canaccord Genuity Group
September 19, 2023 | msn.com
Canaccord Genuity Reiterates 10x Genomics Inc - (TXG) Buy Recommendation
September 27, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
September 19, 2023 | msn.com
NanoString falls afterprelim injunction in Germany in dispute with 10x Genomics (update)
September 18, 2023 | finance.yahoo.com
Unveiling 10x Genomics (TXG)'s Value: Is It Really Priced Right? A Comprehensive Guide
September 14, 2023 | reuters.com
10x Genomics defeats startup's attempt to end gene-analysis patent case
September 14, 2023 | finance.yahoo.com
10x Genomics Expands Gene Expression Flex Offering with New High-Throughput Multiomic Profiling Kit
September 12, 2023 | benzinga.com
Psomagen Puts Spatial Biology and Multiomics in Focus, first CRO to launch 10X Genomics Xenium™ in situ Analyzer services in North America
September 27, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
September 8, 2023 | finance.yahoo.com
10x Genomics (TXG)'s True Worth: A Comprehensive Analysis of Its Market Value
September 8, 2023 | msn.com
10x Genomics: Recent Performance Amplifies My Bullish Conviction
September 5, 2023 | finance.yahoo.com
Study Enabled by 10x Genomics Single Cell and Spatial Technologies Explains Why Immunotherapy is More Effective for Certain Brain Tumors Than Others
August 31, 2023 | msn.com
10x Genomics Inc - (TXG) Price Target Increased by 7.02% to 64.01
August 30, 2023 | finance.yahoo.com
10x Genomics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
August 29, 2023 | finance.yahoo.com
10x Genomics Surpasses 100 Xenium Analyzer Shipments
August 9, 2023 | finance.yahoo.com
We're Not Very Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Rate
August 7, 2023 | msn.com
Morgan Stanley Reiterates 10x Genomics Inc - (TXG) Overweight Recommendation
August 5, 2023 | finanznachrichten.de
10x Genomics, Inc.: 10x Genomics Reports Second Quarter 2023 Financial Results
August 4, 2023 | markets.businessinsider.com
Bank of America Securities Keeps Their Sell Rating on 10x Genomics (TXG)
August 4, 2023 | finance.yahoo.com
Highflier 10x Genomics Sacrifices Breakout As Macro Headwinds Squeeze China
August 4, 2023 | markets.businessinsider.com
Barclays Keeps Their Buy Rating on 10x Genomics (TXG)
August 4, 2023 | finance.yahoo.com
10x Genomics (TXG) Reports Q2 Earnings: What Key Metrics Have to Say
August 3, 2023 | finance.yahoo.com
10x Genomics Reports Second Quarter 2023 Financial Results
August 3, 2023 | finance.yahoo.com
Buy-Zone-Adjacent 10x Genomics Tops Sales Views, But There's A Caveat
July 13, 2023 | msn.com
Goldman Sachs Maintains 10x Genomics Inc - (TXG) Sell Recommendation
July 13, 2023 | finance.yahoo.com
10x Genomics to Report Second Quarter 2023 Financial Results on August 3, 2023
July 13, 2023 | markets.businessinsider.com
Where 10x Genomics Stands With Analysts
See More Headlines
Receive TXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter.

TXG Company Calendar

Last Earnings
8/03/2023
Today
9/27/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TXG
CUSIP
N/A
CIK
1770787
Web
www.10xgenomics.com
Phone
925-401-7300
Fax
N/A
Employees
1,243
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$58.73
High Stock Price Forecast
$75.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+42.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.49)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-166,000,000.00
Net Margins
-30.31%
Pretax Margin
-29.36%
Return on Equity
-21.69%
Return on Assets
-17.11%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.94
Quick Ratio
5.09

Sales & Book Value

Annual Sales
$516.41 million
Price / Sales
9.39
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.99 per share
Price / Book
5.91

Miscellaneous

Outstanding Shares
117,420,000
Free Float
104,913,000
Market Cap
$4.85 billion
Optionable
Optionable
Beta
1.77
The Best High-Yield Dividend Stocks for 2023 Cover
The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Serge Saxonov Ph.D. (Age 46)
    Co-Founder, CEO & Director
    Comp: $837.68k
  • Dr. Benjamin J. Hindson Ph.D. (Age 48)
    Co-Founder, Pres, Chief Scientific Officer & Director
    Comp: $615.96k
  • Mr. Justin J. McAnearMr. Justin J. McAnear (Age 47)
    Chief Financial Officer
    Comp: $535.91k
  • Mr. Eric S. Whitaker Esq. (Age 56)
    Chief Legal Officer
    Comp: $558.97k
  • Mr. James L. Wilbur Ph.D. (Age 58)
    Chief Commercial Officer
    Comp: $390.78k
  • Mr. Michael Schnall-Levin
    Founding Scientist & CTO
  • Ms. Cassie Corneau
    Mang. of Investor Relations and Strategic Fin.
  • Ms. Rebecca Port
    Chief People Officer
  • Mr. James Bryant
    Director of Legal
  • Mr. Nikhil Rao
    Director of Product Management

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













TXG Stock - Frequently Asked Questions

Should I buy or sell 10x Genomics stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last year. There are currently 1 sell rating, 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TXG shares.
View TXG analyst ratings or view top-rated stocks.

What is 10x Genomics' stock price forecast for 2023?

9 brokerages have issued 1-year target prices for 10x Genomics' shares. Their TXG share price forecasts range from $25.00 to $75.00. On average, they expect the company's share price to reach $58.73 in the next year. This suggests a possible upside of 42.2% from the stock's current price.
View analysts price targets for TXG or view top-rated stocks among Wall Street analysts.

How have TXG shares performed in 2023?

10x Genomics' stock was trading at $36.44 at the start of the year. Since then, TXG stock has increased by 13.3% and is now trading at $41.29.
View the best growth stocks for 2023 here.

When is 10x Genomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our TXG earnings forecast.

How were 10x Genomics' earnings last quarter?

10x Genomics, Inc. (NASDAQ:TXG) posted its earnings results on Thursday, August, 3rd. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by $0.14. The firm earned $146.82 million during the quarter, compared to analyst estimates of $139.97 million. 10x Genomics had a negative net margin of 30.31% and a negative trailing twelve-month return on equity of 21.69%. 10x Genomics's revenue for the quarter was up 28.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.57) earnings per share.

What ETFs hold 10x Genomics' stock?

ETFs with the largest weight of 10x Genomics (NASDAQ:TXG) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), ARK Genomic Revolution ETF (ARKG), Fidelity Disruptive Medicine ETF (FMED), ARK Innovation ETF (ARKK), BNY Mellon Innovators ETF (BKIV), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and Principal Healthcare Innovators ETF (BTEC).

What guidance has 10x Genomics issued on next quarter's earnings?

10x Genomics issued an update on its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $600.00 million-$620.00 million, compared to the consensus revenue estimate of $600.73 million.

What is Serge Saxonov's approval rating as 10x Genomics' CEO?

25 employees have rated 10x Genomics Chief Executive Officer Serge Saxonov on Glassdoor.com. Serge Saxonov has an approval rating of 100% among the company's employees. This puts Serge Saxonov in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did 10x Genomics IPO?

(TXG) raised $297 million in an initial public offering on Thursday, September 12th 2019. The company issued 9,000,000 shares at $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen was co-manager.

What is 10x Genomics' stock symbol?

10x Genomics trades on the NASDAQ under the ticker symbol "TXG."

Who are 10x Genomics' major shareholders?

10x Genomics' stock is owned by many different retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (7.32%), BlackRock Inc. (4.65%), Sands Capital Management LLC (3.55%), ARK Investment Management LLC (2.68%), Brown Capital Management LLC (2.65%) and SRS Investment Management LLC (1.87%). Insiders that own company stock include Benjamin J Hindson, Benjamin J Hindson, Bradford Crutchfield, James Wilbur, John R Stuelpnagel, John R Stuelpnagel, Justin J Mcanear, Justin J Mcanear, Mathai Mammen, Serge Saxonov and Sridhar Kosaraju.
View institutional ownership trends.

How do I buy shares of 10x Genomics?

Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 10x Genomics' stock price today?

One share of TXG stock can currently be purchased for approximately $41.29.

How much money does 10x Genomics make?

10x Genomics (NASDAQ:TXG) has a market capitalization of $4.85 billion and generates $516.41 million in revenue each year. The company earns $-166,000,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis.

How many employees does 10x Genomics have?

The company employs 1,243 workers across the globe.

How can I contact 10x Genomics?

10x Genomics' mailing address is 6230 STONERIDGE MALL ROAD, PLEASANTON CA, 94588. The official website for the company is www.10xgenomics.com. The company can be reached via phone at 925-401-7300 or via email at investors@10xgenomics.com.

This page (NASDAQ:TXG) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -